Synthetic Biologics appoints Carol Reed
pharmafile | May 15, 2012 | Appointment | Business Services, Manufacturing and Production, Research and Development, Sales and Marketing | Carol Reed, Synthetic
Synthetic Biologics has appointed Carol Reed as senior vice president of Clinical & Regulatory Affairs.
In this position Reed will be responsible for the design and implementation of all aspects of clinical development – including clinical trials – and will lead the Company’s regulatory initiatives.
Reed brings over 25 years of experience in medical practice and in the biotechnology/pharmaceutical sector, including six years with Clinical Data, a publicly-traded biopharmaceutical company which was acquired by Forest Laboratories.
Most recently Reed served as chief medical officer at Clinical Data from 2005 through 2011, after the company merged with Genaissance Pharmaceuticals where she had served as vice president, Medical Affairs since 2003.
“We are very pleased to add an executive of Carol’s caliber to the Synthetic Biologics’ team. Carol’s broad experience in clinical development, as well as her leadership skills, are expected to be tremendous assets to the Company as we continue to work to build our development pipeline and move our ongoing MS and ALS clinical programs forward,” stated Jeffrey Riley, chief executive at Synthetic Biologics.
Related Content
£10 million boost for synthetic biology
The Biotechnology and Biological Science Research Council (BBSRC) has put up £10 million which can …






